Advertisement

Picture Berlin Partner Health Capital Computational Biology 2022 650x100px
Collaboration › Details

ADC Therapeutics–Morgan Stanley: investor conference, 202209 supply service ADC to participate in Morgan Stanley Annual Global Healthcare Conference

 

Period Period 2022-09-13
Region Region New York, NY
  Country United States (USA)
Organisations Partner, 1st ADC Therapeutics S.A. (NYSE: ADCT)
  Group ADC Therapeutics (Group)
  Partner, 2nd Morgan Stanley & Co. LLC
  Group Morgan Stanley (Group)
Products Product Morgan Stanley Global Healthcare Conference 2022 New York
  Product 2 antibody-drug conjugates (ADC) technology
Person Person Mallik, Ameet (ADC Therapeutics 202205– CEO before Rafael Holdings + 16y at Novartis + McKinsey & Co)
     

ADC Therapeutics S.A.. (9/6/22). "Press Release: ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference". Lausanne.

ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley’s 20th Annual Global Healthcare Conference on Tuesday, September 13th at 11:45 a.m. ET.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.


About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.


Investors

Eugenia Litz
ADC Therapeutics
Eugenia.Litz@adctherapeutics.com
+44 7879 627205

Amanda Hamilton
ADC Therapeutics
amanda.hamilton@adctherapeutics.com
+1 917-288-7023

Media

Mary Ann Ondish
ADC Therapeutics
maryann.ondish@adctherapeutics.com
+1 914-552-4625

   
Record changed: 2022-09-06

Advertisement

Picture Berlin Partner Health Capital Computational Biology 2022 650x200px

More documents for ADC Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2022 650x300




» top